<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-23</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-23</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>66</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>3</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
Natureæ­ç¤ºè¡°è€æ–°ç‚ç—‡æºå¤´ï¼ŒCellæŠ¥é“æ–°å‹å…ç–«æ²»ç–—è¯ç‰©ï¼Œèƒ½å¢å¼ºå·¨å™¬ç»†èƒã€NKç»†èƒå’ŒTç»†èƒæŠ—ç™Œèƒ½åŠ›ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- <strong>è‚¿ç˜¤å¾®ç¯å¢ƒä¸å…ç–«æŠ‘åˆ¶/æ¿€æ´»</strong>ï¼šåˆ©ç”¨å•ç»†èƒå¤šç»„å­¦ä¸ç©ºé—´å›¾è°±ï¼Œæ­ç¤ºGPR116+å‘¨ç»†èƒåœ¨é£Ÿç®¡é³çŠ¶ç»†èƒç™Œä¸­çš„å…ç–«æŠ‘åˆ¶ä½œç”¨ï¼›è¯†åˆ«MMP1+è‚¿ç˜¤ç»†èƒå¯¹è‚¿ç˜¤-å…ç–«ç›¸äº’ä½œç”¨çš„å½±å“ï¼›è§£æè‚¿ç˜¤è€è¯æ€§ä¸å…ç–«æ²»ç–—ç–—æ•ˆé¢„æµ‹ã€‚<br />
- <strong>å…ç–«ç»†èƒåŠŸèƒ½ä¸è°ƒæ§</strong>ï¼šå‘ç°æ–°å‹å·¨å™¬ç»†èƒé¶å‘å…ç–«ç»†èƒå› å­ï¼›ä»£è°¢è°ƒæ§åœ¨é‡å¡‘å…ç–«ç»†èƒå‘½è¿ä¸åŠŸèƒ½ä¸­çš„ä½œç”¨ï¼›M2å·¨å™¬ç»†èƒè¿ç§»ä½“è°ƒæ§å¹²ç»†èƒå½’å·¢æœºåˆ¶ã€‚<br />
- <strong>ç–¾ç—…æœºåˆ¶ä¸æ²»ç–—ç­–ç•¥</strong>ï¼šè§£ææ¢—é˜»æ€§è‚ ç™Œè„‚ä»£è°¢é™·é˜±ï¼›ç¯å¢ƒæ±¡æŸ“é©±åŠ¨å‘¼å¸é“æŠ—ç”Ÿç´ è€è¯åŸºå› å¯Œé›†ï¼›åµå·¢ç™Œå‰ç—…å˜æ¼”åŒ–è¿›ç¨‹ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- <strong>å¤šç»„å­¦ä¸ç©ºé—´æŠ€æœ¯æ•´åˆ</strong>ï¼šå•ç»†èƒè”åˆç©ºé—´ç»„å­¦ï¼ˆå¦‚Visiumï¼‰æˆä¸ºè¯†åˆ«å…³é”®åŸºå› ã€ç»†èƒäºšç¾¤åŠé‡å¡‘å¾®ç¯å¢ƒçš„é‡è¦æ‰‹æ®µã€‚<br />
- <strong>AIä¸æ ‡å‡†åŒ–åˆ†æ</strong>ï¼šscUnifiedç­‰AIå·¥å…·ä¸ºå•ç»†èƒæ•°æ®åˆ†ææä¾›æ ‡å‡†åŒ–èµ„æºã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
UHRF1ç¼ºå¤±é€šè¿‡è¡¨è§‚é—ä¼ è°ƒæ§NPY1RåŸºå› ç”²åŸºåŒ–ï¼ŒåŠ å‰§è‚ é“ç‚ç—‡ï¼›HMGN1/HMGN2å‚ä¸è°ƒæ§æŸ“è‰²è´¨çŠ¶æ€ä¸è½¬å½•ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>ç–¾ç—…æœºåˆ¶ç ”ç©¶</strong>ï¼šè§£æç‚ç—‡æ€§è‚ ç—…ã€æ€¥æ€§é«“ç³»ç™½è¡€ç—…ã€åµå·¢ç™Œã€éå°ç»†èƒè‚ºç™Œã€æ…¢æ€§ç˜™ç—’ã€æµæ„Ÿæ„ŸæŸ“ç­‰ç–¾ç—…çš„å‘ç—…æœºåˆ¶åŠæ²»ç–—é¶ç‚¹ã€‚<br />
*   <strong>ç»†èƒåˆ†åŒ–ä¸å‘è‚²</strong>ï¼šç ”ç©¶èƒšèƒå¹²ç»†èƒå‘èƒ¸è…ºä¸Šçš®ç¥–ç»†èƒçš„åˆ†åŒ–è¿‡ç¨‹ï¼›æ¢ç´¢Etv2+/Flk1+ç¥–ç»†èƒåœ¨å†…çš®ã€é€ è¡€å’Œå¿ƒè„è°±ç³»ä¸­çš„è´¡çŒ®ã€‚<br />
*   <strong>å¾®ç”Ÿç‰©ä¸å®¿ä¸»äº’ä½œ</strong>ï¼šåˆ†æè‚ é“èŒç¾¤-èƒ†æ±é…¸-TLRä¿¡å·è½´åœ¨è†€èƒ±æŸä¼¤ä¸­çš„ä½œç”¨ï¼›è¯„ä¼°æœ‰ç›ŠèŒåœ¨æ¤ç‰©ç”Ÿé•¿ä¸­çš„å½±å“ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>æ–°å‹æ¨¡å‹æ„å»º</strong>ï¼šåˆ©ç”¨äººé¼ åµŒåˆè„‘æ¨¡å‹ç ”ç©¶ç¥ç»èƒ¶è´¨-ç¥ç»å…ƒåŠå°èƒ¶è´¨-å·¨å™¬ç»†èƒäº’ä½œã€‚<br />
*   <strong>é«˜é€šé‡ç»„å­¦åº”ç”¨</strong>ï¼šå¹¿æ³›åº”ç”¨å•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰åŠå…¨è½¬å½•ç»„æµ‹åºï¼Œå®ç°é«˜åˆ†è¾¨ç‡çš„åŸºå› è¡¨è¾¾è°±åˆ†æã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹å£æœé˜¿å¸åŒ¹æ—è¡¥å……å‰‚æ˜¾è‘—é™ä½é˜¿å°”èŒ¨æµ·é»˜ç—‡æŸä¼¤ï¼›æ–°å‹ä¸‰è”ç–—æ³•æ¿€å‘å¼ºæ•ˆå…ç–«æ”»å‡»ç™½è¡€ç—…ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚ é“å¥åº·è¯Šæ–­ï¼šåˆ©ç”¨å·¥ç¨‹ç»†èŒåˆ¶æˆçš„å¾®å‹èƒ¶å›Šæ£€æµ‹è‚ é“å‡ºè¡€ã€‚<br />
- ç™Œç—‡å…ç–«ç–—æ³•ï¼šé€šè¿‡è¯±å¯¼ç™Œç»†èƒåæ­»æ€§å‡‹äº¡ï¼ˆnecroptosisï¼‰å¢å¼ºæŠ—è‚¿ç˜¤å…ç–«ã€‚<br />
- ç¥ç»é€€è¡Œæ€§ç–¾ç—…ï¼šç ”ç©¶æ°¨åŸºé…¸ï¼ˆç²¾æ°¨é…¸ï¼‰å¯¹é˜¿å°”èŒ¨æµ·é»˜ç—‡çš„ä¿æŠ¤ä½œç”¨ã€‚<br />
- å•ç»†èƒæ¯”è¾ƒåˆ†æï¼šå¼€å‘æ·±åº¦å­¦ä¹ å·¥å…·æå‡è·¨ç‰©ç§å•ç»†èƒç ”ç©¶çš„ç½‘ç»œæ¶æ„å¯¹é½ã€‚<br />
- ç©ºé—´è½¬å½•ç»„å­¦ï¼šç³»ç»Ÿæ€§è¯„æµ‹ä¸åŒå¹³å°åœ¨ç¦å°”é©¬æ—å›ºå®šçŸ³èœ¡åŒ…åŸ‹ï¼ˆFFPEï¼‰ç»„ç»‡ä¸Šçš„æ€§èƒ½ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- åˆ›æ–°æ€§åœ°åˆ©ç”¨å·¥ç¨‹ç»†èŒä½œä¸ºä½“å†…è¯Šæ–­å·¥å…·ã€‚<br />
- ç»“åˆä¸‰ç§ç°æœ‰è¯ç‰©å®ç°å…ç–«ç–—æ³•çªç ´ã€‚<br />
- é¦–æ¬¡åˆ©ç”¨æ·±åº¦å­¦ä¹ å·¥å…·ä¼˜åŒ–è·¨ç‰©ç§å•ç»†èƒæ•°æ®æ¯”å¯¹ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (32æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>ç©ºé—´ç»„å­¦ | Nat.Genet. | å•ç»†èƒå¤šç»„å­¦ä¸ç©ºé—´å›¾è°±æ­ç¤ºé£Ÿç®¡é³çŠ¶ç»†èƒç™Œä¸­GPR116+å‘¨ç»†èƒåœ¨ç™Œç—‡è½¬ç§»ä¸­çš„å…ç–«æŠ‘åˆ¶ä½œç”¨</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šBioJournal Link<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å…ç–«ã€Tç»†èƒã€å•ç»†èƒã€ç©ºé—´ç»„å­¦<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503141&amp;idx=1&amp;sn=579b67969db4198c5d04672e5f896078" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>5æœˆæœ€æ–°6+ç”Ÿä¿¡ï¼Œå•ç»†èƒ+ç©ºè½¬åˆ†æMMP1+ è‚¿ç˜¤ç»†èƒå¯¹è‚¿ç˜¤-å…ç–«ç›¸äº’ä½œç”¨çš„å½±å“ï¼Œè¯†åˆ«æŸåŸºå› é˜³æ€§çš„ç»†èƒäºšç¾¤æ˜¯ç›®å‰æµè¡Œçš„å‘æ–‡æ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504020&amp;idx=4&amp;sn=199c6ab8ed44546b5e14bcc2c4b883bc" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>Cell |å•ç»†èƒè”åˆç©ºé—´å‘ç°æ–°å‹å·¨å™¬ç»†èƒé¶å‘å…ç–«ç»†èƒå› å­ï¼Œçœ‹çœ‹å’‹å®éªŒéªŒè¯çš„</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡é’±åŒå­¦<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å·¨å™¬ç»†èƒã€ç»†èƒå› å­ã€å•ç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæ¸…æ™°çš„ç»„å­¦å’Œå®éªŒæ€è·¯<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495648&amp;idx=1&amp;sn=a4b1366289e657d7ba9b137a762c7dd2" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>ã€Šç»†èƒã€‹ï¼šå…ç–«æ²»ç–—é‡ç£…ç‚¸å¼¹è¯ç”Ÿï¼ç§‘å­¦å®¶å‘æ˜æ–°å‹å…ç–«æ²»ç–—è¯ç‰©ï¼Œèƒ½åŒæ—¶å¢å¼ºå·¨å™¬ç»†èƒã€NKç»†èƒå’ŒTç»†èƒæŠ—ç™Œèƒ½åŠ›</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå¥‡ç‚¹è‚¿ç˜¤æ¢ç§˜<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€Tç»†èƒã€å·¨å™¬ç»†èƒã€NKç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šå¯ä»¥è¯´æ˜¯å…ç–«æ²»ç–—é¢†åŸŸçš„é‡ç£…çªç ´äº†ï¼<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&amp;mid=2247503541&amp;idx=1&amp;sn=166c41a64590053cf3ab2076387207f0" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>å•ç»†èƒåˆ†è¾¨ç‡ä¸‹è‚¿ç˜¤å¾®ç¯å¢ƒçš„ä»£è°¢å›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡èœé¸Ÿå›¢<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ä»£è°¢ã€å•ç»†èƒ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzUzMTEwODk0Ng==&amp;mid=2247538196&amp;idx=1&amp;sn=65a37488a53fa93eb69c3a67e9f1bfa4" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>ç”Ÿä¿¡ç»˜å›¾ä¸å†æ„ï¼karyoploteRåŒ…ï¼Œä¸‰åˆ†é’Ÿè½»æ¾ç»˜åˆ¶åŸºå› ç»„æ•°æ®ï¼Œå¿«é€ŸæŒæ¡æŸ“è‰²ä½“å¯è§†åŒ–ä¸æ³¨é‡ŠæŠ€å·§ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šäº‘ç”Ÿä¿¡<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šåŸºå› ç»„ã€ç”Ÿä¿¡ã€RåŒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498512&amp;idx=1&amp;sn=3fdb86b8a84981310215010d613f770f" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>æœ€æ–°8+ç”Ÿä¿¡ï¼Œç»“åˆå•ç»†èƒ+ç©ºè½¬+ 18 ç§ç¨‹åºæ€§ç»†èƒæ­»ï¼Œç€é‡äºå¯¹é¢„åå’Œå…ç–«æ²»ç–—ç–—æ•ˆçš„é¢„æµ‹åŠåŸºå› åŠŸèƒ½éªŒè¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504020&amp;idx=5&amp;sn=b4a975222d0ad0ca08ffa387946b956f" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>7+ç”Ÿä¿¡ï¼ŒåŸºäºå•ç»†èƒå’Œç©ºè½¬è¯†åˆ«ç”Ÿæ€ä½ç‰¹å¼‚æ€§è½¬å½•å’Œç»†èƒç»„æˆç‰¹å¾ï¼Œè¯†åˆ«å…³é”®åŸºå› å¹¶è¿›è¡ŒéªŒè¯ã€‚æ€è·¯æ–°é¢–ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå•ç»†èƒã€è½¬å½•ç»„ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504020&amp;idx=2&amp;sn=643d3559b70494990e2ade86e06a7db4" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>scRNAä¸scBCR-seqè¯†åˆ«ä¸åŒå¹´é¾„æ®µå¥åº·ä¾›ä½“è…¹è†œè…”å’Œå¤–å‘¨è¡€ä¸­BCRåŒæŠ—ä½“Bç»†èƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå•ç»†èƒå¤©åœ°<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šBç»†èƒã€æŠ—ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šé€šè¿‡å•ç»†èƒä¸å…ç–«ç»„åº“ï¼Œç³»ç»Ÿæ¯”è¾ƒä¸åŒå¹´é¾„æ®µäººç±»ä¸å°é¼ Bç»†èƒå—ä½“ç»„æˆï¼Œå‘ç°åŒBCR Bç»†èƒéšå¹´é¾„å¢é•¿è€Œæ˜¾è‘—å¢åŠ ï¼Œä¸”ä¸»è¦æ¥æºäºB1ç»†èƒã€‚è¯¥ç¾¤ä½“å‘ˆç°ç‹¬ç‰¹åŸºå› è¡¨è¾¾è°±ï¼Œæç¤ºå…ç–«è¡°è€ä¼´éšBç»†èƒå—ä½“å¤šæ ·æ€§"è´¨å˜"ï¼Œä¸ºç†è§£å¹´é¾„ç›¸å…³å…ç–«å¤±è°ƒæä¾›äº†æ–°è§†è§’<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247533787&amp;idx=1&amp;sn=a6a57d278f845feb4550e6c57e2e881d" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>é€‰é¢˜æƒ³é¡ºåˆ©æ­ä¸Šå›½è‡ªç„¶ï¼Ÿå±±å¤§å›¢é˜Ÿè¿™ç¯‡â€œè¡¨å‹å·®å¼‚+å…ç–«ç»†èƒ+ç‚ç—‡åŸºå› â€çš„æ¡†æ¶å°±æ˜¯ç°æˆæ¨¡æ¿ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç¥ç»å²›<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€ç‚ç—‡<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&amp;mid=2247497938&amp;idx=1&amp;sn=72cbbdfd621bd7faf5b65494c82353df" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 22 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (29æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE310605 UHRF1 ç¼ºé™·é€šè¿‡è¡¨è§‚é—ä¼ è°ƒæ§ NPY1R åŸºå› ç”²åŸºåŒ–åŠ å‰§è‚ é“ç‚ç—‡</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šinflammationã€epigeneticã€methylationã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Han YananSeries Type : Methylation profiling by arrayOrganism : Homo sapiensEpigenetic modifications play a crucial role in the pathogenesis of inflammatory bowel disease (IBD) by mediating geneâ€“environment interactions. We previously showed that UHRF1, a central regulator of DNA methylation, contributes to cancer progression; however, its function in IBD remains poorly understood. Here, we revealed that UHRF1 is frequently reduced in inflamed tissues of IBD patients and that its deficiency exacerbates intestinal epithelial cell (IEC) damage. Through a multi-level approach incorporating human cell models and an intestinal epithelial-specific Uhrf1 knockout mouse model, we established UHRF1 as a key mitigator of IBD progression. Mechanistically, UHRF1 bound to the NPY1R promoter, promoting its methylation and leading to transcriptional suppression. The NPY1R upregulation resulting from UHRF1 deficiency attenuated cAMPâ€“PKAâ€“CREB signaling in IECs, thereby enhancing NF-ÎºB activation and subsequent pro-inflammatory responses, which compromised intestinal epithelial barrier integrity. Furthermore, we identified miR-141 as a negative regulator of NPY1R, highlighting its potential as a therapeutic agent. Collectively, our results identified the UHRF1â€“NPY1R regulatory axis as a critical epigenetic mechanism in intestinal inflammation and underscored its dual promise for IBD diagnostics and therapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310605" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE310603 UHRF1 ç¼ºé™·é€šè¿‡è¡¨è§‚é—ä¼ è°ƒæ§ NPY1R åŸºå› ç”²åŸºåŒ–åŠ å‰§è‚ é“ç‚ç—‡ [åŸºå› è¡¨è¾¾]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šinflammationã€epigeneticã€methylationã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Han Yanan ; Bai XueSeries Type : Expression profiling by arrayOrganism : Homo sapiensEpigenetic modifications play a crucial role in the pathogenesis of inflammatory bowel disease (IBD) by mediating geneâ€“environment interactions. We previously showed that UHRF1, a central regulator of DNA methylation, contributes to cancer progression; however, its function in IBD remains poorly understood. Here, we revealed that UHRF1 is frequently reduced in inflamed tissues of IBD patients and that its deficiency exacerbates intestinal epithelial cell (IEC) damage. Through a multi-level approach incorporating human cell models and an intestinal epithelial-specific Uhrf1 knockout mouse model, we established UHRF1 as a key mitigator of IBD progression. Mechanistically, UHRF1 bound to the NPY1R promoter, promoting its methylation and leading to transcriptional suppression. The NPY1R upregulation resulting from UHRF1 deficiency attenuated cAMPâ€“PKAâ€“CREB signaling in IECs, thereby enhancing NF-ÎºB activation and subsequent pro-inflammatory responses, which compromised intestinal epithelial barrier integrity. Furthermore, we identified miR-141 as a negative regulator of NPY1R, highlighting its potential as a therapeutic agent. Collectively, our results identified the UHRF1â€“NPY1R regulatory axis as a critical epigenetic mechanism in intestinal inflammation and underscored its dual promise for IBD diagnostics and therapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310603" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>GSE310548 Etv2+ å’Œ Flk1+ ç¥–ç»†èƒå¯¹å†…çš®ã€é€ è¡€å’Œå¿ƒè„è°±ç³»çš„ä¸åŒè´¡çŒ® [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcardiacã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Alleyne Dereck ; Kim Minseo ; Wu Jun ; Kwon Yoojung ; Kim Ye-Ram ; Ul Kabir Ashraf ; Ishahak Matthew ; Millman Jeffrey R. ; Fan Changxu ; Lee Hyung Joo ; Krchma Karen ; Xing Xiaoyun ; Lavine Kory ; Wang Ting ; Choi KyungheeSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe ETS family transcription factor ETV2, VEGFA and its receptor FLK1 are essential for hematopoietic, vascular and cardiac development. Here, we combine dual Etv2 and Flk1 lineage tracing with molecular profiling to define how mesoderm progenitors are allocated to hematopoietic, endothelial, cardiomyocyte and smooth muscle lineages. We demonstrate that hematopoietic, endothelial, and cardiac valves arise from dual Etv2+ and Flk1+ lineages and that Etv2+ and Flk1+ mesoderm contributing to the hemangiogenic fate is molecularly distinct from those generating muscle. Mechanistically, we show that ETV2 cooperates with the BAF chromatin remodeling complex to establish accessibility at ETV2 target loci. Loss of Baf155 expression reduces chromatin accessibility at ETV2 target loci and impairs hemangiogenic lineage specification. This work defines lineage relationships and the molecular circuitry underlying hemangiogenic specification during cardiovascular development.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310548" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE298248 é€‰æ‹©æ€§æ¶ˆé™¤ä¾›ä½“ç»†èŒå¯å®ç°æ¥åˆæ—©æœŸé˜¶æ®µè´¨ç²’åŸºå› è¡¨è¾¾çš„å…¨å±€åˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šbacteriaã€regex:bacter(ia|ial|ium)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Meng Wen ; Nathan Fraikin ; Emma Mettouchi ; Christian Lesterlin ; Elena Espinosa ; Yoshiharu YamaichiSeries Type : Expression profiling by high throughput sequencingOrganism : Escherichia coli ; Sinorhizobium melilotiConjugative plasmids are a major driving force for the dissemination of antimicrobial resistance. During conjugation, plasmid DNA is transferred from the donor cell as a single-stranded (ss) linear molecule. Recent researches highlighted intriguing DNA reactions at the early stage of conjugation that are important for plasmid establishment in the recipient cell, including prompt expression of anti-defense genes. However, genomics-based approaches to investigate plasmid establishment have been challenging, because identical, fully established plasmids in donor cells mask transconjugant-specific signals. To overcome this limitation, we developed a new EDTA method which exploits a donor mutant hypersensitive to hypoosmotic shock. It allows unprecedently quick and efficient Elimination of Donor population for Transconjugant Accumulation. RNAseq analysis revealed highly selective and robust induction of plasmid genes during early stage of conjugation. We experimentally identified +1 sites of 6 possible operons that are matched with ssDNA promoter predictions. We also showed gene expression program is altered in different recipient cells in which plasmid establishment is perturbed. As the EDTA method is straightforward and broadly applicable, it will further understanding of the plasmid establishment processes in new host cell, not only gene expression but also ss to double-stranded DNA conversion and plasmid circularization.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298248" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE280954 åˆ†æ³ŒBiTEçš„Tç»†èƒä¸PD-1é˜»æ–­å‰‚åˆç†è”åˆï¼Œä¿ƒè¿›å±€éƒ¨å…ç–«å¾®ç¯å¢ƒé‡å¡‘ï¼Œä»è€Œå¢å¼ºåµå·¢ç™Œçš„æ²»ç–—ååº”æŒä¹…æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Long Mark ; McGray AJ Robert ; Chiello Jessie LSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusscRNA-seq (5' GEX) was used to examine the peritoneal TME in IE9-mp1-hFRa cells bearing animals treated with FRB-T cell + anti-PD1 therapies. We observed unique TME composition associated with acute and durable responses to combination therapy that was disrupted in progressive disease. Further we found that providing an AD-OVA immunization boost along the course of therapy enhanced favorable TME composition and overall tumor control.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280954" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE280910 äººç±»-å°é¼ åµŒåˆè„‘æ¨¡å‹ç”¨äºç ”ç©¶äººç±»ç¥ç»èƒ¶è´¨ç»†èƒ-ç¥ç»å…ƒå’Œå·¨èƒ¶è´¨ç»†èƒ-å°èƒ¶è´¨ç»†èƒç›¸äº’ä½œç”¨ [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šNeuronalã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jin Mengmeng ; Ma Ziyuan ; Jiang PengSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHuman-mouse chimeric brain models, generated by transplanting human induced pluripotent stem cell (hiPSC)-derived neural cells, are valuable for studying the development and function of human neural cells in vivo. Understanding glial-glial and glial-neuronal interactions is essential for unraveling the complexities of brain function and developing treatments for neurological disorders. To explore these interactions between human neural cells in vivo, we co-engrafted hiPSC-derived neural progenitor cells together with primitive macrophage progenitors into the neonatal mouse brain. This approach creates human-mouse chimeric brains containing human microglia, macroglia (astroglia and oligodendroglia), and neurons. Using super-resolution imaging and 3D reconstruction techniques, we examine the dynamics between human neurons and glia, and observe human microglia pruning synapses of human neurons, and often engulfing neurons themselves, as well as the interactions between human oligodendrocytes and neurons. Single-cell RNA sequencing analysis of the chimeric brain uncovers a close recapitulation of the human glial progenitor cell population, along with a dynamic stage in astroglial development that mirrors the processes found in the human brain. Furthermore, cell-cell communication analysis highlights significant neuronal-glial and macroglial-microglial interactions, especially the interaction between adhesion molecules neurexins and neuroligins. This innovative co-transplantation model opens up new avenues for exploring the complex pathophysiological mechanisms underlying human neurological diseases. It holds particular promise for studying disorders where glial-neuronal interactions and non-cell-autonomous effects play crucial roles.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280910" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE280909 äººç±»-å°é¼ åµŒåˆè„‘æ¨¡å‹ç ”ç©¶äººç±»ç¥ç»èƒ¶è´¨ç»†èƒ-ç¥ç»å…ƒå’Œå·¨èƒ¶è´¨ç»†èƒ-å°èƒ¶è´¨ç»†èƒç›¸äº’ä½œç”¨ [æ‰¹é‡ RNA æµ‹åº]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šNeuronalã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jin Mengmeng ; Ma Ziyuan ; Jiang PengSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHuman-mouse chimeric brain models, generated by transplanting human induced pluripotent stem cell (hiPSC)-derived neural cells, are valuable for studying the development and function of human neural cells in vivo. Understanding glial-glial and glial-neuronal interactions is essential for unraveling the complexities of brain function and developing treatments for neurological disorders. To explore these interactions between human neural cells in vivo, we co-engrafted hiPSC-derived neural progenitor cells together with primitive macrophage progenitors into the neonatal mouse brain. This approach creates human-mouse chimeric brains containing human microglia, macroglia (astroglia and oligodendroglia), and neurons. Using super-resolution imaging and 3D reconstruction techniques, we examine the dynamics between human neurons and glia, and observe human microglia pruning synapses of human neurons, and often engulfing neurons themselves, as well as the interactions between human oligodendrocytes and neurons. Single-cell RNA sequencing analysis of the chimeric brain uncovers a close recapitulation of the human glial progenitor cell population, along with a dynamic stage in astroglial development that mirrors the processes found in the human brain. Furthermore, cell-cell communication analysis highlights significant neuronal-glial and macroglial-microglial interactions, especially the interaction between adhesion molecules neurexins and neuroligins. This innovative co-transplantation model opens up new avenues for exploring the complex pathophysiological mechanisms underlying human neurological diseases. It holds particular promise for studying disorders where glial-neuronal interactions and non-cell-autonomous effects play crucial roles.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280909" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE280054 æŠ‘åˆ¶ ADSS2 ä»‹å¯¼çš„ä»å¤´ AMP ç”Ÿç‰©åˆæˆå¯ä½¿æ€¥æ€§é«“ç³»ç™½è¡€ç—…å¯¹ BH3 æ¨¡æ‹Ÿç‰©é‡æ–°æ•æ„Ÿ [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xin He ; Wei Chen ; Ling LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDe novo purine synthesis is required to promote tumor growth; however, its role in therapy resistance remains elusive. Here, through a dynamic BH3-priming based CRISPR-Cas9 screen, we found that deletion of ADSS2, which encodes for an enzyme functioning in de novo AMP synthesis, re-sensitizes drug resistant acute myeloid leukemia (AML) cells to BH3 mimetics. Single-cell sequencing and metabolomics analyses reveal that high ADSS2 activity in leukemia samples including those with TP53 aberrations inversely correlates with venetoclax responsiveness. Further, we developed anADSS2 antagonist, exhibiting synergism with BH3 mimetics in preclinical AML models. Mechanistically, sensitization to BH3 mimetics mediated by ADSS targeting was associated with downregulated AMPK activity, which governs mitochondrial homeostasis. AMPK activity in resistant cells promotes mitophagy to eliminate damaged mitochondria upon BH3 mimetics treatment. These data demonstrate that AMP synthesis governs venetoclax resistance, and that combining ADSS targeting with BH3 mimetic treatment could represent a promising approach against AML.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280054" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE310067 äººç±»è¾“åµç®¡ä¸Šçš®ç±»å™¨å®˜æºå¸¦TP53çªå˜ï¼Œé‡ç°æµ†æ¶²æ€§è¾“åµç®¡ä¸Šçš®å†…ç™Œï¼ˆSTICï¼‰çš„ç‰¹å¾ - RNAæµ‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€sequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Judith Kraiczy ; Bo YuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHuman fallopian tube epithelial organoids with TP53 mutation recapitulate features of serous tubal intraepithelial carcinoma (STIC),Judith Kraiczy, Bo Yu,Gynecologic Oncology, Volume 203,2025, Pages 198-208, ISSN 0090-8258,https://doi.org/10.1016/j.ygyno.2025.10.038.SUMMARY Objective Serous tubal intraepithelial carcinoma (STIC) is the immediate precursor lesion for high-grade serous ovarian carcinoma (HGSOC) and harbors universal TP53 mutations. The lack of an appropriate in vitro model for STIC presents a major challenge in studying its pathogenesis. We aimed to develop a human in vitro model that mimics STIC lesions. Methods Using CRISPR-Cas9 gene editing, we generated human fallopian tube epithelial organoids with TP53 loss-of-function mutations (TP53-/- FTOs). We characterized TP53-/- FTOs on a cellular and molecular level using immunofluorescence confocal imaging, copy number variation (CNV) analysis, and RNA sequencing. TP53-/- FTOs recapitulated key features of STIC lesions. They exhibited increased proliferation and nuclear abnormalities, including nuclear enlargement and atypical mitotic figures. Copy number variation analysis revealed aneuploidy in some TP53-/- FTOs. Compared to unedited controls, TP53-/- FTOs demonstrated significant transcriptomic changes, including the downregulation of DNA repair genes and upregulation of epithelial-mesenchymal transition (EMT) pathways. Similar to STIC lesions, TP53-/- FTOs showed a marked reduction in ciliated cells and ciliogenesis-associated gene expression. Conclusions These findings suggest that p53 loss in FTOs promotes a proliferative and genomically unstable state that is conducive to carcinogenesis. The TP53-/- FTO model we have generated provides a valuable tool for studying early events in ovarian carcinogenesis and for developing new strategies for the early detection and prevention of ovarian cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310067" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE283535 METTL3 é€šè¿‡è°ƒæ§ CDC25A å’Œ AURKB mRNA çš„ç¨³å®šæ€§ï¼Œä¿ƒè¿›éå°ç»†èƒè‚ºç™Œç»†èƒç³»å¯¹å¥¥å¸Œæ›¿å°¼çš„è€è¯æ€§ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Ryusuke Suzuki ; Minoru Terashima ; Akihiko Ishimura ; Makiko Meguro-Horike ; Shin-ichi Horike ; Yuka Kubota ; Sasithorn Wanna-udom ; Seiji Yano ; Takahisa Takino ; Takeshi SuzukiSeries Type : Expression profiling by arrayOrganism : Homo sapiensOsimertinib, a third-generation EGFR tyrosine kinase inhibitor, is used as a first-line therapy for non-small cell lung cancer (NSCLC) harboring EGFR mutations. Nevertheless, the emergence of acquired drug resistance poses a significant challenge, leading to poor clinical outcomes. METTL3, a key methyltransferase responsible for N6-methyladenosine (m6A) modification of RNA, has been implicated in cancer development and progression across various cancer types. In this study, we explored the role of METTL3 in acquired resistance to osimertinib and assessed its potential as a therapeutic target. Using METTL3 knockdown EGFR-mutated NSCLC cell lines, we found that downregulation of METTL3 suppressed the acquisition of osimertinib resistance. Microarray analysis and qRT-PCR revealed that CDC25A and AURKB are downstream target genes of METTL3, with METTL3 facilitating the stabilization of their mRNAs. Downregulation of these METTL3 target genes also attenuated osimertinib resistance. Furthermore, we evaluated the effects of combining osimertinib with either a METTL3 inhibitor or a CDC25A inhibitor, both of which increased drug efficacy by promoting apoptosis. Collectively, this study highlights the involvement of METTL3 in the initial acquisition of osimertinib resistance and the therapeutic potential of targeting the METTL3-mediated regulatory pathway.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283535" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 19 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (5æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨5æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>å¯¹FFPEç»„ç»‡ä¸­æˆåƒç©ºé—´è½¬å½•ç»„å­¦å¹³å°è¿›è¡Œç³»ç»Ÿæ€§åŸºå‡†æµ‹è¯•</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA comparison of imaging spatial transcriptomics platforms reveals strengths and tradeoffs across technologies using FFPE tissues and integrates insights with RNA sequencing...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/systematic-benchmarking-of-imaging-spatial-transcriptomics-platforms-in-ffpe-tissues/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>è¿™ç§å°å°çš„è¯ä¸¸å¯èƒ½ä¼šæ”¹å˜æˆ‘ä»¬è¯Šæ–­è‚ é“å¥åº·çš„æ–¹å¼ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgutã€regex:gut(-?microbiome)?<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šTiny ingestible spheres filled with engineered bacteria can detect intestinal bleeding by glowing when they encounter heme. Early tests in mice suggest they could become a quick, noninvasive way to monitor gut disease.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251121082046.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ä¸‰è”ç–—æ³•å¯å¼•å‘é’ˆå¯¹ç™½è¡€ç—…çš„å¼ºæ•ˆå…ç–«æ”»å‡»ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€immune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA cutting-edge approach to immunotherapy shows that forcing cancer cells to die through necroptosis can dramatically boost the body's anti-tumor defenses. By combining three existing drugs, scientists reprogrammed malignant B cells so they release danger signals that rally immune cells to fully eliminate leukemia in preclinical models.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251120002609.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>scSpeciesâ€”â€”å¢å¼ºæ¯”è¾ƒå•ç»†èƒç ”ç©¶ä¸­çš„ç½‘ç»œç»“æ„å¯¹é½</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA new deep learning tool improves cross species single cell comparisons and integrates insights with RNA sequencing to enhance...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/scspecies-enhancement-of-network-architecture-alignment-in-comparative-single-cell-studies/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>ç®€å•çš„æ°¨åŸºé…¸è¡¥å……å‰‚èƒ½æ˜¾è‘—å‡è½»é˜¿å°”èŒ¨æµ·é»˜ç—…é€ æˆçš„æŸå®³ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers discovered that the common amino acid arginine can block harmful AÎ² aggregation and reduce its toxic effects in Alzheimerâ€™s disease models. In flies and mice, oral arginine lowered plaque levels, reduced inflammation, and improved behavior. Its strong safety record and low cost make it a promising repurposing candidate. The findings hint at a surprisingly simple path toward more accessible AD therapies.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251121090731.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>ç”Ÿä¿¡</td>
<td>10</td>
</tr>
<tr>
<td>å•ç»†èƒ</td>
<td>10</td>
</tr>
<tr>
<td>å…ç–«</td>
<td>7</td>
</tr>
<tr>
<td>ä»£è°¢</td>
<td>5</td>
</tr>
<tr>
<td>è‚¿ç˜¤</td>
<td>3</td>
</tr>
<tr>
<td>å·¨å™¬ç»†èƒ</td>
<td>3</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>3</td>
</tr>
<tr>
<td>Neuronal</td>
<td>3</td>
</tr>
<tr>
<td>T cell</td>
<td>3</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>cancer</td>
<td>3</td>
</tr>
<tr>
<td>scRNA</td>
<td>3</td>
</tr>
<tr>
<td>leukemia</td>
<td>3</td>
</tr>
<tr>
<td>inflammation</td>
<td>3</td>
</tr>
<tr>
<td>ç‚ç—‡</td>
<td>2</td>
</tr>
<tr>
<td>Tç»†èƒ</td>
<td>2</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>2</td>
</tr>
<tr>
<td>cardiac</td>
<td>2</td>
</tr>
<tr>
<td>regex:bacter(ia</td>
<td>ial</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (22æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504020&amp;idx=3&amp;sn=86eb6065ff2a22a1ee28c9ec305bbba1" target="_blank" rel="noopener noreferrer">æœ€æ–°10åˆ†ç”Ÿä¿¡ï¼Œå•ç»†èƒ+ç©ºè½¬è¯†åˆ«ECM é‡å¡‘ç›¸å…³æˆçº¤ç»´ç»†èƒï¼Œå¹¶ç¡®å®šå…³é”®åŸºå› è¿›è¡Œå®éªŒéªŒè¯ï¼Œå¹²æ¹¿ç»“åˆå€¼å¾—å€Ÿé‰´ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2MTExNTkwNA==&amp;mid=2247573597&amp;idx=1&amp;sn=cce49b056e66542eec96599d422d8a7b" target="_blank" rel="noopener noreferrer">è¡°è€ä¸æ˜¯ç£¨æŸï¼Œè€Œæ˜¯æ³„æ¼ï¼Natureæ­ç¤ºç‚ç—‡æ–°æºå¤´ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248745&amp;idx=2&amp;sn=fee3e72795ac05ea8ae4b8b05adbb7dd" target="_blank" rel="noopener noreferrer">æµ…è°ˆç”Ÿç‰©ä¿¡æ¯ä¸ªæ€§åŒ–åˆ†æ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248745&amp;idx=1&amp;sn=8fc913ab63a3bd13c77a654d34e6d10c" target="_blank" rel="noopener noreferrer">çº¯ç”Ÿä¿¡åˆ†æçš„å¤©èŠ±æ¿ï¼å“ˆåŒ»å¤§åˆ©ç”¨å¤šç»„å­¦+æ³›ç™Œåˆ†æï¼Œè¿˜èƒ½èåˆå•ç»†èƒï¼Œæ‹¿ä¸‹6åˆ†SCIå®è‡³åå½’ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NDcxMzYwNg==&amp;mid=2247490967&amp;idx=1&amp;sn=306dd07a471df6ec47ee681871367b91" target="_blank" rel="noopener noreferrer">IF=16.6 Cancer Res æ–‡çŒ®è§£è¯»| æ¢—é˜»æ€§è‚ ç™Œçš„è„‚ä»£è°¢é™·é˜±è¢«æ­å¼€ï¼Œé¦™è‰é…®æŠ‘åˆ¶æ–¹æ¡ˆå¯ç›´æ¥å¥—ç”¨ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650527&amp;idx=3&amp;sn=fadd190c0e59a4dda224970a38509c69" target="_blank" rel="noopener noreferrer">Cell Repï¼šç‹ç’‹/éƒ‘é›ªç‡•æ­ç¤ºç¯å¢ƒæ±¡æŸ“é©±åŠ¨å‘¼å¸é“æŠ—ç”Ÿç´ è€è¯åŸºå› çš„å¯Œé›†ä¸ä¼ æ’­</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650527&amp;idx=2&amp;sn=b6b4d78227037fd256a03b09cf0face1" target="_blank" rel="noopener noreferrer">ä¸æ­¢æ˜¯èƒ½é‡ï¼šä»£è°¢è°ƒæ§å¦‚ä½•é‡å¡‘å…ç–«ç»†èƒçš„å‘½è¿ä¸åŠŸèƒ½</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510431&amp;idx=2&amp;sn=a0c5493b8fa50d281c566866d7f438ed" target="_blank" rel="noopener noreferrer">æ–°æœºåˆ¶è§è§£ï¼åŒæµå¤§å­¦é™„å±ä¸œæ–¹åŒ»é™¢ç­‰å•ä½å‘æ–‡ï¼šå…‹æœè‚¿ç˜¤è€è¯æ€§å’Œæé«˜ç—…ç†ç¼“è§£ç‡çš„æ½œåœ¨ç­–ç•¥</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493035&amp;idx=1&amp;sn=a4c2f9eddbfb1871f7aa3e99b5343137" target="_blank" rel="noopener noreferrer">æœ€æ–°10+çº¯ç”Ÿä¿¡ï¼Œç©ºè½¬Visium+COSMxå®šä¹‰æ²»ç–—ååº”ç›¸å…³çš„nicheï¼ç”Ÿä¿¡åˆ†ææ–°æ€è·¯ï¼Œå€¼å¾—æ”¶è—å­¦ä¹ ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&amp;mid=2247488251&amp;idx=1&amp;sn=84e921a8027c13dc304102117f16f557" target="_blank" rel="noopener noreferrer">M2å·¨å™¬ç»†èƒè¿ç§»ä½“åŒé‡ä¿¡å·å¯¼å¼•å¹²ç»†èƒå½’å·¢</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504020&amp;idx=1&amp;sn=bb5a5fb1be4aaa313cba86a8c76edd51" target="_blank" rel="noopener noreferrer">åˆšåˆšå‘è¡¨çš„7.5åˆ†ç”Ÿä¿¡ï¼Œä¸€ç§ç”¨äºç²¾å‡†æ³›ç™Œåˆ†ç±»çš„å¤šè¡¨å¾æ·±åº¦å­¦ä¹ æ¡†æ¶ï¼åªè¦æœ‰æŠ€æœ¯ï¼Œè¿˜åšä»€ä¹ˆå®éªŒï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247569062&amp;idx=2&amp;sn=39e9b0661b10cf803b9302ec75112e12" target="_blank" rel="noopener noreferrer">å¯¹è¯ | å…¨çƒ14äº¿äººè¡€å‹å¤±æ§ï¼æ–¯å¦ç¦ä¸“å®¶æ•™ä½ ç”¨å…«æ‹›å®ˆæŠ¤å¿ƒè„å¥åº· | Bilingual</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzNzY2NDgyOQ==&amp;mid=2247493355&amp;idx=1&amp;sn=e6b0fac0d8667a9440f856ab148fc88f" target="_blank" rel="noopener noreferrer">kmodRï¼šå¸¦å¼‚å¸¸æ£€æµ‹çš„ K-Means èšç±»</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507540&amp;idx=2&amp;sn=7ef8253b1f0a943023e7b6978967a061" target="_blank" rel="noopener noreferrer">è§£ç åµå·¢ç™Œå‰ç—…å˜ï¼šç©ºé—´è›‹ç™½ç»„å­¦å‹¾å‹’è¾“åµç®¡ä¸Šçš®å†…ç™Œå‘é«˜åˆ†çº§æµ†æ¶²æ€§åµå·¢ç™Œçš„æ¼”åŒ–è¿›ç¨‹</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyNDI1MzE0NA==&amp;mid=2247490166&amp;idx=1&amp;sn=12f9831b75ec6fabbe9523b925c66161" target="_blank" rel="noopener noreferrer">scUnifiedï¼šå•ç»†èƒæ•°æ®åˆ†æçš„AIæ ‡å‡†åŒ–èµ„æº</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248745&amp;idx=7&amp;sn=a576934adb07c3d095a5a31e0bd1da52" target="_blank" rel="noopener noreferrer">67åˆ†å·¨ä½œï¼Œå¸¦ä½ ç”¨çˆ†ç«çš„ä»£è°¢é‡ç¼–ç¨‹å®ç°å¼¯é“è¶…è½¦</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248745&amp;idx=6&amp;sn=2885e6ef8e84f80f2e8c9f6bf86281e5" target="_blank" rel="noopener noreferrer">Cell Genomæœ€æ–°åŠ›ä½œï¼å¤šç»„å­¦+å­Ÿå¾·å°”éšæœºåŒ–åˆ†æï¼Œç ´è§£è¡€æ¸…ä»£è°¢ç‰©ä¸æ…¢æ€§ç–¾ç—…çš„é—ä¼ å…³è”ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248745&amp;idx=5&amp;sn=6b2baee99abd420f4d80e47a3878e73c" target="_blank" rel="noopener noreferrer">28 æ ·æœ¬ IF40.4ï¼è§£å¯†ç‹çº¢é˜³é™¢å£«å›¢é˜Ÿçš„å•ç»†èƒåˆ›æ–°å¯†ç </a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248745&amp;idx=4&amp;sn=adef34d67ae4786e18940a9723c3e058" target="_blank" rel="noopener noreferrer">æœ€æ–°27+ç”Ÿä¿¡ï¼ŒåŸæ¥åªåšäº†è¿™äº›æ“ä½œï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzMzY5NDk3NA==&amp;mid=2247493365&amp;idx=1&amp;sn=bccf95184d1450b71195bb53f39c2a95" target="_blank" rel="noopener noreferrer">NMï½œæ­»äº¡é£é™©é£™å‡ 22.4 å€ï¼1250 ä¾‹æ•°æ®æ­ç¤ºï¼Œç›¸æ¯”è¿œå¤„è½¬ç§»ï¼Œè¿™ä»¶äº‹æ‰æ˜¯ç™Œç—‡è‡´æ­»çš„â€œå¤´å·æ€æ‰‹â€ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790394&amp;idx=2&amp;sn=f5c62cc169d8bdc2a431c5e52f644630" target="_blank" rel="noopener noreferrer">åœ°çƒå¥åº·çš„éšå½¢å®ˆæŠ¤è€…â€”â€”å¾®ç”Ÿç‰©ä¸¨Cell Press Live</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790480&amp;idx=3&amp;sn=d927a19cc3a2829b8386f7904036391e" target="_blank" rel="noopener noreferrer">Cellå­åˆŠï¼šGLP-1ç±»è¯ç‰©ï¼Œå‘æŒ¥å…¨èº«æ€§æŠ—è¡°è€ä½œç”¨</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (19æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282695" target="_blank" rel="noopener noreferrer">GSE282695 STAT3 é€šè¿‡é‡ç¼–ç¨‹ç‚ç—‡è¯±å¯¼çš„å¾®ç”Ÿç‰©é˜²å¾¡ååº”æ¥è°ƒèŠ‚å·¨å™¬ç»†èƒä¸­çš„ç—…åŸä½“æ§åˆ¶å’Œæ¸…é™¤ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279638" target="_blank" rel="noopener noreferrer">GSE279638 åˆ©ç”¨è½¬åº§å­è¿›è¡Œç”Ÿç‰©ä¼ æ„Ÿå™¨å¼•å¯¼çš„å…¨åŸºå› ç»„è¯±å˜æµ‹åºç»“æœ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310716" target="_blank" rel="noopener noreferrer">GSE310716 ä¸åŒç»†èƒå¤–åŸºè´¨ç¡¬åº¦ä¸‹ç¥ç»æ¯ç»†èƒç˜¤ç»†èƒçš„å…¨è½¬å½•ç»„å­¦æ•°æ®</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310396" target="_blank" rel="noopener noreferrer">GSE310396 Etv2+ å’Œ Flk1+ ç¥–ç»†èƒå¯¹å†…çš®ã€é€ è¡€å’Œå¿ƒè„è°±ç³»çš„ä¸åŒè´¡çŒ®</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304598" target="_blank" rel="noopener noreferrer">GSE304598 äººç±»iPScåˆ†åŒ–ä¸ºèƒ¸è…ºä¸Šçš®ç¥–ç»†èƒçš„æ‰¹é‡RNAæµ‹åºæ—¶é—´è¿›ç¨‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295457" target="_blank" rel="noopener noreferrer">GSE295457 å¤šç»„å­¦ç ”ç©¶æ­ç¤º CCL3 é©±åŠ¨ä¸æ˜åŸå› æ…¢æ€§ç˜™ç—’ä¸­çš„ç¥ç»å…ƒæ•åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291111" target="_blank" rel="noopener noreferrer">GSE291111 è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…¨èº«åŒ–ç–—å¯æåŒ–æ•ˆåº”Tç»†èƒåˆ†åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290679" target="_blank" rel="noopener noreferrer">GSE290679 ä»£è°¢é€‚åº”ä»¥äºšç¾¤ç‰¹å¼‚æ€§æ–¹å¼é‡å¡‘äººç±»å±é‡ç–¾ç—…ï¼ˆä¼´æˆ–ä¸ä¼´è„“æ¯’ç—‡ï¼‰ä¸­çš„ CD4 T ç»†èƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271812" target="_blank" rel="noopener noreferrer">GSE271812 ç—…æ¯’å’Œå…ç–«æŸä¼¤ä¸ç»„ç»‡ä¿®å¤ä¹‹é—´çš„å¹³è¡¡å¯é¢„é˜²è‡´å‘½æ€§æµæ„Ÿæ„ŸæŸ“å¯¼è‡´çš„æ­»äº¡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300561" target="_blank" rel="noopener noreferrer">GSE300561 ä½æ°®å’Œæœ‰ç›Šç»†èŒå¯¹æ ¹å’ŒèŒç”Ÿé•¿çš„æ‹Ÿå—èŠ¥çš„å½±å“ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280009" target="_blank" rel="noopener noreferrer">GSE280009 æŠ‘åˆ¶ ADSS2 ä»‹å¯¼çš„ä»å¤´ AMP ç”Ÿç‰©åˆæˆå¯ä½¿æ€¥æ€§é«“ç³»ç™½è¡€ç—…å¯¹ BH3 æ¨¡æ‹Ÿç‰©é‡æ–°æ•æ„Ÿ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310557" target="_blank" rel="noopener noreferrer">GSE310557 å¤šç»„å­¦åˆ†ææ­ç¤ºäº†å¾®ç”Ÿç‰©ç¾¤-èƒ†æ±é…¸-TLRä¿¡å·é€šè·¯é©±åŠ¨é—´è´¨æ€§è†€èƒ±ç‚è†€èƒ±æŸä¼¤çš„ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310429" target="_blank" rel="noopener noreferrer">GSE310429 äººç±»è¾“åµç®¡ä¸Šçš®ç±»å™¨å®˜æºå¸¦TP53çªå˜ï¼Œé‡ç°äº†æµ†æ¶²æ€§è¾“åµç®¡ä¸Šçš®å†…ç™Œï¼ˆSTICï¼‰çš„ç‰¹å¾ - LP-WGS</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303156" target="_blank" rel="noopener noreferrer">GSE303156 ç³–å°¿ç—…æ‚£è€…ï¼ˆä¼´æˆ–ä¸ä¼´ä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³è„‚è‚ªæ€§è‚ç‚ï¼‰å¾ªç¯å¤–æ³Œä½“microRNAè°±åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291949" target="_blank" rel="noopener noreferrer">GSE291949 HMGN1 å’Œ HMGN2 è¢«å‹Ÿé›†åˆ°ä¹™é…°åŒ–å’Œå«æœ‰ç»„è›‹ç™½å˜ä½“ H2A.Z çš„æ ¸å°ä½“ä¸Šï¼Œä»è€Œè°ƒèŠ‚æŸ“è‰²è´¨çŠ¶æ€å’Œè½¬å½•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291947" target="_blank" rel="noopener noreferrer">GSE291947 HMGN1 å’Œ HMGN2 è¢«å‹Ÿé›†åˆ°ä¹™é…°åŒ–å’Œå«æœ‰ç»„è›‹ç™½å˜ä½“ H2A.Z çš„æ ¸å°ä½“ä¸Šï¼Œä»è€Œè°ƒèŠ‚æŸ“è‰²è´¨çŠ¶æ€å’Œè½¬å½•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310181" target="_blank" rel="noopener noreferrer">GSE310181 Vnut ç¼ºå¤±å¯¹ CD4+ T ç»†èƒåˆ†åŒ–ä¸º Th1 ç»†èƒè¿‡ç¨‹ä¸­åŸºå› è¡¨è¾¾çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297896" target="_blank" rel="noopener noreferrer">GSE297896 äººç±»å¼‚ç§ç§»æ¤æ’æ–¥ååº”ä¸­çš„å…‹éš†æ€§ T ç»†èƒååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289110" target="_blank" rel="noopener noreferrer">GSE289110 ä¸åŒçš„å…ç–«è°ƒèŠ‚é€šè·¯ä»‹å¯¼æ¶æ€§å‘¨å›´ç¥ç»é˜ç˜¤çš„æ”¾å°„æ²»ç–—ååº” [scRNA-Seq]</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-22 21:33</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>